New England Capital Financial Advisors’s Biogen BIIB Stock Holding History

New England Capital Financial Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13	Closed	-$1.63K	–	421
2025 Q2	$1.63K	Hold	13	–	–	﹤0.01%	347
2025 Q1	$1.78K	Sell	13 -50	-79%	-$7.15K	﹤0.01%	314
2024 Q4	$9.63K	Hold	63	–	–	﹤0.01%	239
2024 Q3	$12.2K	Sell	63 -50	-44%	-$10.5K	0.01%	216
2024 Q2	$26.2K	Hold	113	–	–	0.01%	151
2024 Q1	$24.4K	Hold	113	–	–	0.01%	158
2023 Q4	$29.2K	Hold	113	–	–	0.02%	141
2023 Q3	$29K	Hold	113	–	–	0.02%	138
2023 Q2	$32.2K	Hold	113	–	–	0.02%	137
2023 Q1	$31.4K	Hold	113	–	–	0.02%	149
2022 Q4	$32.3K	Buy	+113	New	+$31.9K	0.02%	150

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

New England Capital Financial Advisors's BIIB Position: Q3 2025 in Review

New England Capital Financial Advisors sold out of Biogen (BIIB) in Q3 2025, closing a stake of 13 shares — an estimated $1.63K sold.

New England Capital Financial Advisors first reported a position in BIIB in Q4 2022 and held it in 11 quarters. The position peaked at $32.3K in Q4 2022. 906 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

New England Capital Financial Advisors reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
New England Capital Financial Advisors sold 13 Biogen shares in Q3 2025, an estimated $1.63K.
New England Capital Financial Advisors first reported a position in Biogen in Q4 2022 and held it in 11 quarters.
New England Capital Financial Advisors's Biogen position peaked at $32.3K in Q4 2022.
906 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on New England Capital Financial Advisors's 13F filing for Q3 2025, filed 22 Oct 2025.